These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29587661)

  • 1. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    Le Page C; Rahimi K; Köbel M; Tonin PN; Meunier L; Portelance L; Bernard M; Nelson BH; Bernardini MQ; Bartlett JMS; Bachvarov D; Gotlieb WH; Gilks B; McAlpine JN; Nachtigal MW; Piché A; Watson PH; Vanderhyden B; Huntsman DG; Provencher DM; Mes-Masson AM
    BMC Cancer; 2018 Mar; 18(1):347. PubMed ID: 29587661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
    Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
    J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
    Dong F; Davineni PK; Howitt BE; Beck AH
    Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.
    Le Page C; Köbel M; de Ladurantaye M; Rahimi K; Madore J; Babinszky S; Bachvarov DR; Bachvarova M; Beauchamp MC; Cass CE; Chadwick D; Colleen C; Damaraju S; Dufour J; Gotlieb WH; Kalloger SE; Portelance L; McAlpine JN; Matte I; Piché A; Shaw P; Roehrl MH; Vanderhyden BC; Watson PH; Huntsman DG; Provencher DM; Mes-Masson AM
    Biopreserv Biobank; 2013 Apr; 11(2):83-93. PubMed ID: 24845429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
    Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
    J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.
    Köbel M; Rahimi K; Rambau PF; Naugler C; Le Page C; Meunier L; de Ladurantaye M; Lee S; Leung S; Goode EL; Ramus SJ; Carlson JW; Li X; Ewanowich CA; Kelemen LE; Vanderhyden B; Provencher D; Huntsman D; Lee CH; Gilks CB; Mes Masson AM
    Int J Gynecol Pathol; 2016 Sep; 35(5):430-41. PubMed ID: 26974996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histotype classification of ovarian carcinoma: A comparison of approaches.
    Peres LC; Cushing-Haugen KL; Anglesio M; Wicklund K; Bentley R; Berchuck A; Kelemen LE; Nazeran TM; Gilks CB; Harris HR; Huntsman DG; Schildkraut JM; Rossing MA; Köbel M; Doherty JA
    Gynecol Oncol; 2018 Oct; 151(1):53-60. PubMed ID: 30121132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
    Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved survival in women with BRCA-associated ovarian carcinoma.
    Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
    Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    Gan A; Green AR; Nolan CC; Martin S; Deen S
    Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
    J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
    ; Goode EL; Block MS; Kalli KR; Vierkant RA; Chen W; Fogarty ZC; Gentry-Maharaj A; Tołoczko A; Hein A; Bouligny AL; Jensen A; Osorio A; Hartkopf A; Ryan A; Chudecka-Głaz A; Magliocco AM; Hartmann A; Jung AY; Gao B; Hernandez BY; Fridley BL; McCauley BM; Kennedy CJ; Wang C; Karpinskyj C; de Sousa CB; Tiezzi DG; Wachter DL; Herpel E; Taran FA; Modugno F; Nelson G; Lubiński J; Menkiszak J; Alsop J; Lester J; García-Donas J; Nation J; Hung J; Palacios J; Rothstein JH; Kelley JL; de Andrade JM; Robles-Díaz L; Intermaggio MP; Widschwendter M; Beckmann MW; Ruebner M; Jimenez-Linan M; Singh N; Oszurek O; Harnett PR; Rambau PF; Sinn P; Wagner P; Ghatage P; Sharma R; Edwards RP; Ness RB; Orsulic S; Brucker SY; Johnatty SE; Longacre TA; Ursula E; McGuire V; Sieh W; Natanzon Y; Li Z; Whittemore AS; Anna A; Staebler A; Karlan BY; Gilks B; Bowtell DD; Høgdall E; Candido dos Reis FJ; Steed H; Campbell IG; Gronwald J; Benítez J; Koziak JM; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; García MJ; Fasching PA; Kommoss S; Deen S; Kjaer SK; Menon U; Brenton JD; Pharoah PDP; Chenevix-Trench G; Huntsman DG; Winham SJ; Köbel M; Ramus SJ
    JAMA Oncol; 2017 Dec; 3(12):e173290. PubMed ID: 29049607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
    Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
    Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO).
    Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Santón A; Gonzalez BO; López-Reig R; Hardisson D; Vera-Sempere F; Illueca C; Vieites B; López-Guerrero JA; Palacios J; Poveda A
    Am J Surg Pathol; 2020 Feb; 44(2):149-161. PubMed ID: 31498173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.